<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35563001</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>9</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>21</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4610</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23094610</ELocationID><Abstract><AbstractText>The degeneration and dysfunction of neurons are key features of neurodegenerative diseases (NDs). Currently, one of the main challenges facing researchers and clinicians is the ability to obtain reliable diagnostic tools that will allow for the diagnosis of NDs as early as possible and the detection of neuronal dysfunction, preferably in the presymptomatic stage. Additionally, better tools for assessing disease progression in this group of disorders are also being sought. The ideal biomarker must have high sensitivity and specificity, be easy to measure, give reproducible results, and reflect the disease progression. Molecular biomarkers include miRNAs and extracellular microvesicles known as exosomes. They may be measured in two extracellular fluids of the highest importance in NDs, i.e., cerebrospinal fluid (CSF) and blood. The aim of the current review is to summarize the pathophysiology of the four most frequent NDs-i.e., Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS)-as well as current progress in the research into miRNAs as biomarkers in these major neurodegenerative diseases. In addition, we discuss the possibility of using miRNA-based therapies in the treatment of neurodegenerative diseases, and present the limitations of this type of therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doroszkiewicz</LastName><ForeName>Julia</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9937-4974</Identifier><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groblewska</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5406-1149</Identifier><AffiliationInfo><Affiliation>Department of Biochemical Diagnostics, University Hospital in Bia&#x142;ystok, 15-269 Bialystok, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mroczko</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-4075-8479</Identifier><AffiliationInfo><Affiliation>Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SUB/1/DN/22/005/1198, SUB/1/DN/22/003/1198</GrantID><Agency>Medical University of Bia&#x142;ystok</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055354" MajorTopicYN="Y">Exosomes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">epigenetics</Keyword><Keyword MajorTopicYN="N">molecular biomarkers</Keyword><Keyword MajorTopicYN="N">multiple sclerosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>14</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35563001</ArticleId><ArticleId IdType="pmc">PMC9100918</ArticleId><ArticleId IdType="doi">10.3390/ijms23094610</ArticleId><ArticleId IdType="pii">ijms23094610</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>JPND.  [(accessed on 19 March 2022)].  Available online:  https://www.neurodegenerationresearch.eu/</Citation></Reference><Reference><Citation>Stephenson J., Nutma E., van der Valk P., Amor S. Inflammation in CNS neurodegenerative diseases. Immunology. 2018;154:204&#x2013;219. doi: 10.1111/imm.12922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12922</ArticleId><ArticleId IdType="pmc">PMC5980185</ArticleId><ArticleId IdType="pubmed">29513402</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Kukreti R., Saso L., Kukreti S. Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules. 2019;24:1583. doi: 10.3390/molecules24081583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules24081583</ArticleId><ArticleId IdType="pmc">PMC6514564</ArticleId><ArticleId IdType="pubmed">31013638</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-R&#xed;o M., Moreno Caballero M., Manuel G&#xf3;rriz S&#xe1;ez J., M&#xed;nguez-Castellanos A. Diagnosis of Neurodegenerative Diseases: The Clinical Approach. Curr. Alzheimer Res. 2016;13:469&#x2013;474. doi: 10.2174/1567205013666151116141603.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205013666151116141603</ArticleId><ArticleId IdType="pubmed">26567736</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson R.M., Hadjichrysanthou C., Evans S., Wong M.M. Why do so many clinical trials of therapies for Alzheimer&#x2019;s disease fail? Lancet. 2017;390:2327&#x2013;2329. doi: 10.1016/S0140-6736(17)32399-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32399-1</ArticleId><ArticleId IdType="pubmed">29185425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P., Riederer P., O&#x2019;Bryant S.E., Verbeek M.M., Dubois B., Visser P.J., Jellinger K.A., Engelborghs S., Ramirez A., Parnetti L., et al. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J. Biol. Psychiatry. 2018;19:244&#x2013;328. doi: 10.1080/15622975.2017.1375556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622975.2017.1375556</ArticleId><ArticleId IdType="pmc">PMC5916324</ArticleId><ArticleId IdType="pubmed">29076399</ArticleId></ArticleIdList></Reference><Reference><Citation>Laterza O.F., Hendrickson R.C., Wagner J.A. Molecular Biomarkers. Drug Inf. J. 2007;41:573&#x2013;585. doi: 10.1177/009286150704100504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/009286150704100504</ArticleId></ArticleIdList></Reference><Reference><Citation>Broza Y.Y., Zhou X., Yuan M., Qu D., Zheng Y., Vishinkin R., Khatib M., Wu W., Haick H. Disease Detection with Molecular Biomarkers: From Chemistry of Body Fluids to Nature-Inspired Chemical Sensors. Chem. Rev. 2019;119:11761&#x2013;11817. doi: 10.1021/acs.chemrev.9b00437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00437</ArticleId><ArticleId IdType="pubmed">31729868</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien J., Hayder H., Zayed Y., Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018;9:402. doi: 10.3389/fendo.2018.00402.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00402</ArticleId><ArticleId IdType="pmc">PMC6085463</ArticleId><ArticleId IdType="pubmed">30123182</ArticleId></ArticleIdList></Reference><Reference><Citation>Saliminejad K., Khorram Khorshid H.R., Soleymani Fard S., Ghaffari S.H. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J. Cell. Physiol. 2019;234:5451&#x2013;5465. doi: 10.1002/jcp.27486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.27486</ArticleId><ArticleId IdType="pubmed">30471116</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan S., Kenny A., Medina M., Engel T., Jimenez-Mateos E.M. MicroRNAs in Neurodegenerative Diseases. Int. Rev. Cell Mol. Biol. 2017;334:309&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838542</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal M., Biswas A. Molecular diagnostics of neurodegenerative disorders. Front. Mol. Biosci. 2015;2:54. doi: 10.3389/fmolb.2015.00054.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2015.00054</ArticleId><ArticleId IdType="pmc">PMC4585189</ArticleId><ArticleId IdType="pubmed">26442283</ArticleId></ArticleIdList></Reference><Reference><Citation>Zen K., Zhang C.-Y. Circulating MicroRNAs: A novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 2012;32:326&#x2013;348. doi: 10.1002/med.20215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20215</ArticleId><ArticleId IdType="pubmed">22383180</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasso M., Piscopo P., Confaloni A., Denti M.A. Circulating miRNAs as Biomarkers for Neurodegenerative Disorders. Molecules. 2014;19:6891&#x2013;6910. doi: 10.3390/molecules19056891.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules19056891</ArticleId><ArticleId IdType="pmc">PMC6271879</ArticleId><ArticleId IdType="pubmed">24858274</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes O., Chertkow H., Wang E., Schipper H. MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Curr. Genom. 2009;10:154&#x2013;168. doi: 10.2174/138920209788185252.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920209788185252</ArticleId><ArticleId IdType="pmc">PMC2705849</ArticleId><ArticleId IdType="pubmed">19881909</ArticleId></ArticleIdList></Reference><Reference><Citation>Giraldez A.J., Cinalli R.M., Glasner M.E., Enright A.J., Thomson J.M., Baskerville S., Hammond S.M., Bartel D.P., Schier A.F. MicroRNAs regulate brain morphogenesis in zebrafish. Science. 2005;308:833&#x2013;838. doi: 10.1126/science.1109020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1109020</ArticleId><ArticleId IdType="pubmed">15774722</ArticleId></ArticleIdList></Reference><Reference><Citation>Adlakha Y.K., Saini N. Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128. Mol. Cancer. 2014;13:33. doi: 10.1186/1476-4598-13-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1476-4598-13-33</ArticleId><ArticleId IdType="pmc">PMC3936914</ArticleId><ArticleId IdType="pubmed">24555688</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos K., Malenica I., Metpally R., Courtright A., Rakela B., Beach T., Shill H., Adler C., Sabbagh M., Villa S., et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases correlate with disease status and features of pathology. PLoS ONE. 2014;9:e94839. doi: 10.1371/journal.pone.0094839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0094839</ArticleId><ArticleId IdType="pmc">PMC4010405</ArticleId><ArticleId IdType="pubmed">24797360</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju&#x17a;wik C.A., Drake S.S., Zhang Y., Paradis-Isler N., Sylvester A., Amar-Zifkin A., Douglas C., Morquette B., Moore C.S., Fournier A.E. microRNA dysregulation in neurodegenerative diseases: A systematic review. Prog. Neurobiol. 2019;182 doi: 10.1016/j.pneurobio.2019.101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2019.101664</ArticleId><ArticleId IdType="pubmed">31356849</ArticleId></ArticleIdList></Reference><Reference><Citation>Manna I., De Benedittis S., Quattrone A., Maisano D., Iaccino E., Quattrone A. Exosomal miRNAs as Potential Diagnostic Biomarkers in Alzheimer&#x2019;s Disease. Pharmaceuticals. 2020;13:243. doi: 10.3390/ph13090243.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph13090243</ArticleId><ArticleId IdType="pmc">PMC7559720</ArticleId><ArticleId IdType="pubmed">32932746</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz J., Takousis P., Wohlers I., Itua I.O.G., Dobricic V., R&#xfc;cker G., Binder H., Middleton L., Ioannidis J.P.A., Perneczky R., et al. Meta-analyses identify differentially expressed micrornas in Parkinson&#x2019;s disease. Ann. Neurol. 2019;85:835&#x2013;851. doi: 10.1002/ana.25490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25490</ArticleId><ArticleId IdType="pubmed">30990912</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo I., Bubacco L., Greggio E. Exosomes-associated neurodegeneration and progression of Parkinson&#x2019;s disease. Am. J. Neurodegener. Dis. 2012;1:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560468</ArticleId><ArticleId IdType="pubmed">23383394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalluri R., LeBleu V.S. The biology, function, and biomedical applications of exosomes. Science. 2020;367 doi: 10.1126/science.aau6977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aau6977</ArticleId><ArticleId IdType="pmc">PMC7717626</ArticleId><ArticleId IdType="pubmed">32029601</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares Martins T., Trindade D., Vaz M., Campelo I., Almeida M., Trigo G., da Cruz e Silva O.A.B., Henriques A.G. Diagnostic and therapeutic potential of exosomes in Alzheimer&#x2019;s disease. J. Neurochem. 2021;156:162&#x2013;181. doi: 10.1111/jnc.15112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15112</ArticleId><ArticleId IdType="pubmed">32618370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ngolab J., Trinh I., Rockenstein E., Mante M., Florio J., Trejo M., Masliah D., Adame A., Masliah E., Rissman R.A. Brain-derived exosomes from dementia with Lewy bodies propagate &#x3b1;-synuclein pathology. Acta Neuropathol. Commun. 2017;5:46. doi: 10.1186/s40478-017-0445-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0445-5</ArticleId><ArticleId IdType="pmc">PMC5466770</ArticleId><ArticleId IdType="pubmed">28599681</ArticleId></ArticleIdList></Reference><Reference><Citation>Harischandra D.S., Rokad D., Neal M.L., Ghaisas S., Manne S., Sarkar S., Panicker N., Zenitsky G., Jin H., Lewis M., et al. Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of &#x3b1;-synuclein. Sci. Signal. 2019;12 doi: 10.1126/scisignal.aau4543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aau4543</ArticleId><ArticleId IdType="pmc">PMC6435331</ArticleId><ArticleId IdType="pubmed">30862700</ArticleId></ArticleIdList></Reference><Reference><Citation>Soria Lopez J.A., Gonz&#xe1;lez H.M., L&#xe9;ger G.C. Alzheimer&#x2019;s disease. Handb. Clin. Neurol. 2019;167:231&#x2013;255. doi: 10.1016/B978-0-12-804766-8.00013-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-804766-8.00013-3</ArticleId><ArticleId IdType="pubmed">31753135</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimer&#x2019;s Association . Alzheimer&#x2019;s Facts and Figures Report. Alzheimer&#x2019;s Association; Singapore: 2020. p. 1.</Citation></Reference><Reference><Citation>Atri A. The Alzheimer&#x2019;s Disease Clinical Spectrum: Diagnosis and Management. Med. Clin. N. Am. 2019;103:263&#x2013;293. doi: 10.1016/j.mcna.2018.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcna.2018.10.009</ArticleId><ArticleId IdType="pubmed">30704681</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer&#x2019;s disease. Hum. Mol. Genet. 2010;19:R12&#x2013;R20. doi: 10.1093/hmg/ddq160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq160</ArticleId><ArticleId IdType="pmc">PMC2875049</ArticleId><ArticleId IdType="pubmed">20413653</ArticleId></ArticleIdList></Reference><Reference><Citation>Calsolaro V., Edison P. Neuroinflammation in Alzheimer&#x2019;s disease: Current evidence and future directions. Alzheimer&#x2019;s Dement. 2016;12:719&#x2013;732. doi: 10.1016/j.jalz.2016.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.02.010</ArticleId><ArticleId IdType="pubmed">27179961</ArticleId></ArticleIdList></Reference><Reference><Citation>Shao W., Peng D., Wang X. Genetics of Alzheimer&#x2019;s disease: From pathogenesis to clinical usage. J. Clin. Neurosci. 2017;45:1&#x2013;8. doi: 10.1016/j.jocn.2017.06.074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2017.06.074</ArticleId><ArticleId IdType="pubmed">28869135</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner H., Winkler E., Edbauer D., Prokop S., Basset G., Yamasaki A., Kostka M., Haass C. PEN-2 Is an Integral Component of the &#x3b3;-Secretase Complex Required for Coordinated Expression of Presenilin and Nicastrin. J. Biol. Chem. 2002;277:39062&#x2013;39065. doi: 10.1074/jbc.C200469200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C200469200</ArticleId><ArticleId IdType="pubmed">12198112</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R.J., Gustafson D.R., Hardy J. The genetic architecture of Alzheimer&#x2019;s disease: Beyond APP, PSENs and APOE. Neurobiol. Aging. 2012;33:437&#x2013;456. doi: 10.1016/j.neurobiolaging.2010.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.03.025</ArticleId><ArticleId IdType="pmc">PMC2980860</ArticleId><ArticleId IdType="pubmed">20594621</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez W., Morales R., Maracaja-Coutinho V., Parra V., Nassif M. Down syndrome and Alzheimer&#x2019;s disease: Common molecular traits beyond the amyloid precursor protein. Aging. 2020;12:1011. doi: 10.18632/aging.102677.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.102677</ArticleId><ArticleId IdType="pmc">PMC6977673</ArticleId><ArticleId IdType="pubmed">31918411</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A., Das S., Hyman B.T. APOE and Alzheimer&#x2019;s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches. Lancet Neurol. 2021;20:68. doi: 10.1016/S1474-4422(20)30412-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30412-9</ArticleId><ArticleId IdType="pmc">PMC8096522</ArticleId><ArticleId IdType="pubmed">33340485</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson N.D. State of the science on mild cognitive impairment (MCI) CNS Spectr. 2019;24:78&#x2013;87. doi: 10.1017/S1092852918001347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852918001347</ArticleId><ArticleId IdType="pubmed">30651152</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloy M.E., Napolioni V., Han S.S., Le Guen Y., Greicius M.D. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4. JAMA Neurol. 2020;77:849&#x2013;862. doi: 10.1001/jamaneurol.2020.0414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.0414</ArticleId><ArticleId IdType="pmc">PMC7154955</ArticleId><ArticleId IdType="pubmed">32282020</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K., Zetterberg H. Biomarkers for Alzheimer&#x2019;s disease: Current status and prospects for the future. J. Intern. Med. 2018;284:643&#x2013;663. doi: 10.1111/joim.12816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12816</ArticleId><ArticleId IdType="pubmed">30051512</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992;359:322&#x2013;325. doi: 10.1038/359322a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/359322a0</ArticleId><ArticleId IdType="pubmed">1383826</ArticleId></ArticleIdList></Reference><Reference><Citation>Galozzi S., Marcus K., Barkovits K. Amyloid-&#x3b2; as a biomarker for Alzheimer&#x2019;s disease: Quantification methods in body fluids. Expert Rev. Proteom. 2015;12:343&#x2013;354. doi: 10.1586/14789450.2015.1065183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14789450.2015.1065183</ArticleId><ArticleId IdType="pubmed">26153725</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K. Prediction of Alzheimer&#x2019;s disease using the CSF A&#x3b2;42/A&#x3b2;40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007;23:316&#x2013;320. doi: 10.1159/000100926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000100926</ArticleId><ArticleId IdType="pubmed">17374949</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B., Lautner R., Andreasson U., &#xd6;hrfelt A., Portelius E., Bjerke M., H&#xf6;ltt&#xe4; M., Ros&#xe9;n C., Olsson C., Strobel G., et al. CSF and blood biomarkers for the diagnosis of Alzheimer&#x2019;s disease: A systematic review and meta-analysis. Lancet Neurol. 2016;15:673&#x2013;684. doi: 10.1016/S1474-4422(16)00070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(16)00070-3</ArticleId><ArticleId IdType="pubmed">27068280</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. A Review of Fluid Biomarkers for Alzheimer&#x2019;s Disease: Moving from CSF to Blood. Neurol. Ther. 2017;6:15&#x2013;24. doi: 10.1007/s40120-017-0073-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40120-017-0073-9</ArticleId><ArticleId IdType="pmc">PMC5520819</ArticleId><ArticleId IdType="pubmed">28733960</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarbrick S., Wragg N., Ghosh S., Stolzing A. Systematic Review of miRNA as Biomarkers in Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2019;56:6156&#x2013;6167. doi: 10.1007/s12035-019-1500-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1500-y</ArticleId><ArticleId IdType="pmc">PMC6682547</ArticleId><ArticleId IdType="pubmed">30734227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sempere L.F., Freemantle S., Pitha-Rowe I., Moss E., Dmitrovsky E., Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004;5 doi: 10.1186/gb-2004-5-3-r13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-3-r13</ArticleId><ArticleId IdType="pmc">PMC395763</ArticleId><ArticleId IdType="pubmed">15003116</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy B., Lee E., Li T., Rampersaud M. Role of miRNAs in Neurodegeneration: From Disease Cause to Tools of Biomarker Discovery and Therapeutics. Genes. 2022;13:425. doi: 10.3390/genes13030425.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13030425</ArticleId><ArticleId IdType="pmc">PMC8951370</ArticleId><ArticleId IdType="pubmed">35327979</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert S.S., Horr&#xe9; K., Nicola&#xef; L., Papadopoulou A.S., Mandemakers W., Silahtaroglu A.N., Kauppinen S., Delacourte A., De Strooper B. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer&#x2019;s disease correlates with increased BACE1/&#x3b2;-secretase expression. Proc. Natl. Acad. Sci. USA. 2008;105:6415&#x2013;6420. doi: 10.1073/pnas.0710263105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0710263105</ArticleId><ArticleId IdType="pmc">PMC2359789</ArticleId><ArticleId IdType="pubmed">18434550</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiko T., Nakagawa K., Tsuduki T., Furukawa K., Arai H., Miyazawa T. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer&#x2019;s disease. J. Alzheimer&#x2019;s Dis. 2014;39:253&#x2013;259. doi: 10.3233/JAD-130932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-130932</ArticleId><ArticleId IdType="pubmed">24157723</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M.C., Van Nostrand W.E. Degradation of soluble and fibrillar amyloid &#x3b2;-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry. 2010;49:1127&#x2013;1136. doi: 10.1021/bi901994d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi901994d</ArticleId><ArticleId IdType="pmc">PMC2819544</ArticleId><ArticleId IdType="pubmed">20050683</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanavade M.J., Parulekar R.S., Kamble S.A., Sonawane K.D. Molecular modeling approach to explore the role of cathepsin B from Hordeum vulgare in the degradation of A&#x3b2; peptides. Mol. Biosyst. 2015;12:162&#x2013;168. doi: 10.1039/C5MB00718F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C5MB00718F</ArticleId><ArticleId IdType="pubmed">26568474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakamoto T., Saito H., Ishii K., Takahashi H., Tanabe S., Ogasawara Y. Aluminum inhibits proteolytic degradation of amyloid &#x3b2; peptide by cathepsin D: A potential link between aluminum accumulation and neuritic plaque deposition. FEBS Lett. 2006;580:6543&#x2013;6549. doi: 10.1016/j.febslet.2006.10.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2006.10.075</ArticleId><ArticleId IdType="pubmed">17112520</ArticleId></ArticleIdList></Reference><Reference><Citation>CTSD Cathepsin D [Homo sapiens (Human)]&#x2014;Gene&#x2014;NCBI.  [(accessed on 19 March 2022)]; Available online:  https://www.ncbi.nlm.nih.gov/gene?Db=gene&amp;Cmd=ShowDetailView&amp;TermToSearch=1509.</Citation></Reference><Reference><Citation>Tiribuzi R., Crispoltoni L., Porcellati S., Di Lullo M., Florenzano F., Pirro M., Bagaglia F., Kawarai T., Zampolini M., Orlacchio A., et al. MiR128 up-regulation correlates with impaired amyloid &#x3b2;(1-42) degradation in monocytes from patients with sporadic Alzheimer&#x2019;s disease. Neurobiol. Aging. 2014;35:345&#x2013;356. doi: 10.1016/j.neurobiolaging.2013.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.08.003</ArticleId><ArticleId IdType="pubmed">24064186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Han W., Xu Y., Li D., Xue Q. Serum mir-128 serves as a potential diagnostic biomarker for Alzheimer&#x2019;s disease. Neuropsychiatr. Dis. Treat. 2021;17:269&#x2013;275. doi: 10.2147/NDT.S290925.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/NDT.S290925</ArticleId><ArticleId IdType="pmc">PMC7853421</ArticleId><ArticleId IdType="pubmed">33542630</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Z., Chen Y., Xie W., Liu X., Zhu Y., Zhu Y. Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3&#x3b2; pathway in chronic cerebral hypoperfusion rats. Eur. J. Pharmacol. 2018;819:1&#x2013;8. doi: 10.1016/j.ejphar.2017.10.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2017.10.027</ArticleId><ArticleId IdType="pubmed">29042207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Rapp J., Rainone S., H&#xe9;bert S.S. MicroRNAs underlying memory deficits in neurodegenerative disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2017;73:79&#x2013;86. doi: 10.1016/j.pnpbp.2016.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2016.04.011</ArticleId><ArticleId IdType="pubmed">27117821</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau P., Bossers K., Janky R., Salta E., Frigerio C.S., Barbash S., Rothman R., Sierksma A.S.R., Thathiah A., Greenberg D., et al. Alteration of the microRNA network during the progression of Alzheimer&#x2019;s disease. EMBO Mol. Med. 2013;5:1613&#x2013;1634. doi: 10.1002/emmm.201201974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201201974</ArticleId><ArticleId IdType="pmc">PMC3799583</ArticleId><ArticleId IdType="pubmed">24014289</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y., Zhang J., Sun X., Ma G., Luo G., Miao Z., Song L. miR-132 improves the cognitive function of rats with Alzheimer&#x2019;s disease by inhibiting the MAPK1 signal pathway. Exp. Ther. Med. 2020;20 doi: 10.3892/etm.2020.9288.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2020.9288</ArticleId><ArticleId IdType="pmc">PMC7571341</ArticleId><ArticleId IdType="pubmed">33093897</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C., Meng X., Mai D., Xu K., Qu S. Overexpression of miR-132-3p contributes to neuronal protection in in vitro and in vivo models of Alzheimer&#x2019;s disease. Behav. Brain Res. 2022;417 doi: 10.1016/j.bbr.2021.113584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2021.113584</ArticleId><ArticleId IdType="pubmed">34536429</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Q., Xiang Y., Li D., Liang J., Zhang X., Zhou F., Qiao M., Nie Y., He Y., Cheng J., et al. MiR-124-3p attenuates hyperphosphorylation of tau proteininduced apoptosis via caveolin-1-PI3K/Akt/GSK3&#x3b2; pathway in N2a/APP695swe cells. Oncotarget. 2017;8:24314&#x2013;24326. doi: 10.18632/oncotarget.15149.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15149</ArticleId><ArticleId IdType="pmc">PMC5421849</ArticleId><ArticleId IdType="pubmed">28186985</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheignon C., Tomas M., Bonnefont-Rousselot D., Faller P., Hureau C., Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer&#x2019;s disease. Redox Biol. 2018;14:450&#x2013;464. doi: 10.1016/j.redox.2017.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.redox.2017.10.014</ArticleId><ArticleId IdType="pmc">PMC5680523</ArticleId><ArticleId IdType="pubmed">29080524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Tu Q., Liu M. MicroRNA-125b regulates Alzheimer&#x2019;s disease through SphK1 regulation. Mol. Med. Rep. 2018;18:2373&#x2013;2380. doi: 10.3892/mmr.2018.9156.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2018.9156</ArticleId><ArticleId IdType="pubmed">29901156</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.J., Dolios G., Wang R., Liao F.F. Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal MicroRNA expression. PLoS ONE. 2014;9 doi: 10.1371/journal.pone.0090770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090770</ArticleId><ArticleId IdType="pmc">PMC3942478</ArticleId><ArticleId IdType="pubmed">24595404</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheinerman K.S., Tsivinsky V.G., Abdullah L., Crawford F., Umansky S.R. Plasma microRNA biomarkers for detection of mild cognitive impairment: Biomarker validation study. Aging. 2013;5:925&#x2013;938. doi: 10.18632/aging.100624.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.100624</ArticleId><ArticleId IdType="pmc">PMC3883708</ArticleId><ArticleId IdType="pubmed">24368295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj S., Laskowska-Kaszub K., Debski K.J., Wojsiat J., Dabrowski M., Gabryelewicz T., Kuznicki J., Wojda U. Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer&#x2019;s disease patients from non-demented subjects. Oncotarget. 2017;8:16122. doi: 10.18632/oncotarget.15109.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.15109</ArticleId><ArticleId IdType="pmc">PMC5369952</ArticleId><ArticleId IdType="pubmed">28179587</ArticleId></ArticleIdList></Reference><Reference><Citation>Gui Y., Liu H., Zhang L., Lv W., Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6:37043&#x2013;37053. doi: 10.18632/oncotarget.6158.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.6158</ArticleId><ArticleId IdType="pmc">PMC4741914</ArticleId><ArticleId IdType="pubmed">26497684</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeever P.M., Schneider R., Taghdiri F., Weichert A., Multani N., Brown R.A., Boxer A.L., Karydas A., Miller B., Robertson J., et al. MicroRNA Expression Levels Are Altered in the Cerebrospinal Fluid of Patients with Young-Onset Alzheimer&#x2019;s Disease. Mol. Neurobiol. 2018;55:8826&#x2013;8841. doi: 10.1007/s12035-018-1032-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-1032-x</ArticleId><ArticleId IdType="pmc">PMC6208843</ArticleId><ArticleId IdType="pubmed">29603092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugli G., Cohen A.M., Bennett D.A., Shah R.C., Fields C.J., Hernandez A.G., Smalheiser N.R. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS ONE. 2015;10:e0139233. doi: 10.1371/journal.pone.0139233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0139233</ArticleId><ArticleId IdType="pmc">PMC4591334</ArticleId><ArticleId IdType="pubmed">26426747</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T.T., Liu C.G., Gao S.C., Zhang Y., Wang P.C. The Serum Exosome Derived MicroRNA-135a, -193b, and -384 Were Potential Alzheimer&#x2019;s Disease Biomarkers. Biomed. Environ. Sci. 2018;31:87&#x2013;96. doi: 10.3967/BES2018.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3967/BES2018.011</ArticleId><ArticleId IdType="pubmed">29606187</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaraj S., Want A., Laskowska-Kaszub K., Fesiuk A., Vaz S., Logarinho E., Wojda U. Candidate alzheimer&#x2019;s disease biomarker mir-483-5p lowers tau phosphorylation by direct erk1/2 repression. Int. J. Mol. Sci. 2021;22:22. doi: 10.3390/ijms22073653.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22073653</ArticleId><ArticleId IdType="pmc">PMC8037306</ArticleId><ArticleId IdType="pubmed">33915734</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbaz A., Carcaillon L., Kab S., Moisan F. Epidemiology of Parkinson&#x2019;s disease. Rev. Neurol. 2016;172:14&#x2013;26. doi: 10.1016/j.neurol.2015.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2015.09.012</ArticleId><ArticleId IdType="pubmed">26718594</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling H., Massey L.A., Lees A.J., Brown P., Day B.L. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson&#x2019;s disease. Brain. 2012;135:1141&#x2013;1153. doi: 10.1093/brain/aws038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws038</ArticleId><ArticleId IdType="pmc">PMC3326257</ArticleId><ArticleId IdType="pubmed">22396397</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher D.A., Lees A.J., Schrag A. What are the most important nonmotor symptoms in patients with Parkinson&#x2019;s disease and are we missing them? Mov. Disord. 2010;25:2493&#x2013;2500. doi: 10.1002/mds.23394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23394</ArticleId><ArticleId IdType="pubmed">20922807</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier S., Duyckaerts C. Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? Cell Tissue Res. 2018;373:149&#x2013;160. doi: 10.1007/s00441-018-2854-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-018-2854-6</ArticleId><ArticleId IdType="pubmed">29869713</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajares M., Rojo A.I., Manda G., Bosc&#xe1; L., Cuadrado A. Inflammation in Parkinson&#x2019;s Disease: Mechanisms and Therapeutic Implications. Cells. 2020;9:1687. doi: 10.3390/cells9071687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9071687</ArticleId><ArticleId IdType="pmc">PMC7408280</ArticleId><ArticleId IdType="pubmed">32674367</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton A.B., Farrer M.J., Bonifati V. The genetics of Parkinson&#x2019;s disease: Progress and therapeutic implications. Mov. Disord. 2013;28:14&#x2013;23. doi: 10.1002/mds.25249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25249</ArticleId><ArticleId IdType="pmc">PMC3578399</ArticleId><ArticleId IdType="pubmed">23389780</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa E., Vila M., Klein C., Rascol O. LRRK2 in Parkinson disease: Challenges of clinical trials. Nat. Rev. Neurol. 2020;16:97&#x2013;107. doi: 10.1038/s41582-019-0301-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-019-0301-2</ArticleId><ArticleId IdType="pubmed">31980808</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J., Roh&#xe9; C.F., Riboldazzi G., Antonini A., Albani G., Mauro A., et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson&#x2019;s disease. Eur. J. Hum. Genet. 2006;14:322&#x2013;331. doi: 10.1038/sj.ejhg.5201539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5201539</ArticleId><ArticleId IdType="pubmed">16333314</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein C., Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson&#x2019;s disease. Curr. Opin. Neurol. 2007;20:453&#x2013;464. doi: 10.1097/WCO.0b013e3281e6692b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0b013e3281e6692b</ArticleId><ArticleId IdType="pubmed">17620882</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P.-L., Chen Y., Zhang C.-H., Wang Y.-X., Fernandez-Funez P. Genetics of Parkinson&#x2019;s disease and related disorders. J. Med. Genet. 2018;55:73&#x2013;80. doi: 10.1136/jmedgenet-2017-105047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2017-105047</ArticleId><ArticleId IdType="pubmed">29151060</ArticleId></ArticleIdList></Reference><Reference><Citation>Eusebi P., Giannandrea D., Biscetti L., Abraha I., Chiasserini D., Orso M., Calabresi P., Parnetti L. Diagnostic utility of cerebrospinal fluid &#x3b1;-synuclein in Parkinson&#x2019;s disease: A systematic review and meta-analysis. Mov. Disord. 2017;32:1389&#x2013;1400. doi: 10.1002/mds.27110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27110</ArticleId><ArticleId IdType="pubmed">28880418</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako W., Murakami N., Izumi Y., Kaji R. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: Evidence from a meta-analysis. Mov. Disord. 2014;29:1599&#x2013;1605. doi: 10.1002/mds.26036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26036</ArticleId><ArticleId IdType="pubmed">25258345</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., Salvadori N., Lisetti V., Tambasco N., Rossi A., et al. Differential role of CSF alpha-synuclein species, tau, and A&#xce;242 in Parkinson&#x2019;s Disease. Front. Aging Neurosci. 2014;6 doi: 10.3389/fnagi.2014.00053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2014.00053</ArticleId><ArticleId IdType="pmc">PMC3978246</ArticleId><ArticleId IdType="pubmed">24744728</ArticleId></ArticleIdList></Reference><Reference><Citation>Majbour N.K., Vaikath N.N., Van Dijk K.D., Ardah M.T., Varghese S., Vesterager L.B., Montezinho L.P., Poole S., Safieh-Garabedian B., Tokuda T., et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson&#x2019;s disease. Mol. Neurodegener. 2016;11:1&#x2013;15. doi: 10.1186/s13024-016-0072-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0072-9</ArticleId><ArticleId IdType="pmc">PMC4717559</ArticleId><ArticleId IdType="pubmed">26782965</ArticleId></ArticleIdList></Reference><Reference><Citation>Parnetti L., Gaetani L., Eusebi P., Paciotti S., Hansson O., El-Agnaf O., Mollenhauer B., Blennow K., Calabresi P. CSF and blood biomarkers for Parkinson&#x2019;s disease. Lancet Neurol. 2019;18:573&#x2013;586. doi: 10.1016/S1474-4422(19)30024-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30024-9</ArticleId><ArticleId IdType="pubmed">30981640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lotankar S., Prabhavalkar K.S., Bhatt L.K. Biomarkers for Parkinson&#x2019;s Disease: Recent Advancement. Neurosci. Bull. 2017;33:585&#x2013;597. doi: 10.1007/s12264-017-0183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-017-0183-5</ArticleId><ArticleId IdType="pmc">PMC5636742</ArticleId><ArticleId IdType="pubmed">28936761</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito Y. Oxidized DJ-1 as a possible biomarker of Parkinson&#x2019;s disease. J. Clin. Biochem. Nutr. 2014;54:138&#x2013;144. doi: 10.3164/jcbn.13-108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.13-108</ArticleId><ArticleId IdType="pmc">PMC4042152</ArticleId><ArticleId IdType="pubmed">24894116</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs C.E., Wang Y., Kong B., Woo T.-U.W., Iyer L.K., Sonntag K.C. Midbrain dopamine neurons in Parkinson&#x2019;s disease exhibit a dysregulated miRNA and target-gene network. Brain Res. 2015;1618:111&#x2013;121. doi: 10.1016/j.brainres.2015.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2015.05.021</ArticleId><ArticleId IdType="pmc">PMC4522231</ArticleId><ArticleId IdType="pubmed">26047984</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Neuropathology of sporadic Parkinson&#x2019;s disease: Evaluation and changes of concepts. Mov. Disord. 2012;27:8&#x2013;30. doi: 10.1002/mds.23795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23795</ArticleId><ArticleId IdType="pubmed">22081500</ArticleId></ArticleIdList></Reference><Reference><Citation>Titze-de-Almeida S.S., Soto-S&#xe1;nchez C., Fernandez E., Koprich J.B., Brotchie J.M., Titze-de-Almeida R. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson&#x2019;s Disease. Cells. 2020;9:841. doi: 10.3390/cells9040841.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040841</ArticleId><ArticleId IdType="pmc">PMC7226753</ArticleId><ArticleId IdType="pubmed">32244357</ArticleId></ArticleIdList></Reference><Reference><Citation>Margis R., Margis R., Rieder C.R.M. Identification of blood microRNAs associated to Parkinso&#x144;s disease. J. Biotechnol. 2011;152:96&#x2013;101. doi: 10.1016/j.jbiotec.2011.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbiotec.2011.01.023</ArticleId><ArticleId IdType="pubmed">21295623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardo L.F., Coto E., De Mena L., Ribacoba R., Moris G., Men&#xe9;ndez M., Alvarez V. Profile of microRNAs in the plasma of Parkinson&#x2019;s disease patients and healthy controls. J. Neurol. 2013;260:1420&#x2013;1422. doi: 10.1007/s00415-013-6900-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-6900-8</ArticleId><ArticleId IdType="pubmed">23543376</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo S.K., Petillo D., Kang U.J., Resau J.H., Berryhill B., Linder J., Forsgren L., Neuman L.A., Tan A.C. Plasma-Based Circulating MicroRNA Biomarkers for Parkinson&#x2019;s Disease. J. Parkinsons Dis. 2012;2:321&#x2013;331. doi: 10.3233/JPD-012144.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-012144</ArticleId><ArticleId IdType="pubmed">23938262</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong X., Huang M., Chen L. Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson&#x2019;s Disease. Eneuro. 2022;9:ENEURO.0393-21.2021. doi: 10.1523/ENEURO.0393-21.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0393-21.2021</ArticleId><ArticleId IdType="pmc">PMC8805200</ArticleId><ArticleId IdType="pubmed">34983831</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es M.A., Hardiman O., Chio A., Al-Chalabi A., Pasterkamp R.J., Veldink J.H., van den Berg L.H. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulisz D. Amyotrophic lateral sclerosis: Disease state overview. Am. J. Manag. Care. 2018;24:S320&#x2013;S326.</Citation><ArticleIdList><ArticleId IdType="pubmed">30207670</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin X., Peng Q., Zeng Z., Chen Z., Lin L., Deng Y., Huang X., Xu J., Wu H., Huang S., et al. Interleukin-1A 2889C/T polymorphism and risk of Alzheimer&#x2019;s disease: A meta-analysis based on 32 case-control studies. J. Neurol. 2012;259:1519&#x2013;1529. doi: 10.1007/s00415-011-6381-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-011-6381-6</ArticleId><ArticleId IdType="pubmed">22234841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosco D.A., Morfini G., Karabacak N.M., Song Y., Gros-Louis F., Pasinelli P., Goolsby H., Fontaine B.A., Lemay N., McKenna-Yasek D., et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403. doi: 10.1038/nn.2660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2660</ArticleId><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T., Rothstein J.D. Glial cells in amyotrophic lateral sclerosis. Exp. Neurol. 2014;262:111&#x2013;120. doi: 10.1016/j.expneurol.2014.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.05.015</ArticleId><ArticleId IdType="pmc">PMC4241182</ArticleId><ArticleId IdType="pubmed">24859452</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim G., Gautier O., Tassoni-Tsuchida E., Ma X.R., Gitler A.D. ALS Genetics: Gains, Losses, and Implications for Future Therapies. Neuron. 2020;108:822&#x2013;842. doi: 10.1016/j.neuron.2020.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.022</ArticleId><ArticleId IdType="pmc">PMC7736125</ArticleId><ArticleId IdType="pubmed">32931756</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler R.L., Dokholyan N.V. The Complex Molecular Biology of Amyotrophic Lateral Sclerosis (ALS) Prog. Mol. Biol. Transl. Sci. 2012;107:215&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605887</ArticleId><ArticleId IdType="pubmed">22482452</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R., Isaacs A.M. C9orf72-mediated ALS and FTD: Multiple pathways to disease. Nat. Rev. Neurol. 2018;14:544&#x2013;558. doi: 10.1038/s41582-018-0047-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0047-2</ArticleId><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraemer B.C., Schuck T., Wheeler J.M., Robinson L.C., Trojanowski J.Q., Lee V.M.Y., Schellenberg G.D. Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010;119:409&#x2013;419. doi: 10.1007/s00401-010-0659-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0659-0</ArticleId><ArticleId IdType="pmc">PMC2880609</ArticleId><ArticleId IdType="pubmed">20198480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Wang H., Qiao T., Yang B., Aliaga L., Qiu L., Tan W., Salameh J., McKenna-Yasek D.M., Smith T., et al. Partial loss of TDP-43 function causes phenotypes of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2014;111 doi: 10.1073/pnas.1322641111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1322641111</ArticleId><ArticleId IdType="pmc">PMC3970502</ArticleId><ArticleId IdType="pubmed">24616503</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V., Phaneuf D., Dupr&#xe9; N., Petri S., Strong M., Kriz J., Julien J.-P. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear factor &#x3ba;B&#x2013;mediated pathogenic pathways. J. Exp. Med. 2011;208:2429&#x2013;2447. doi: 10.1084/jem.20111313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111313</ArticleId><ArticleId IdType="pmc">PMC3256969</ArticleId><ArticleId IdType="pubmed">22084410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishigaki S., Sobue G. Importance of Functional Loss of FUS in FTLD/ALS. Front. Mol. Biosci. 2018;5:44. doi: 10.3389/fmolb.2018.00044.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2018.00044</ArticleId><ArticleId IdType="pmc">PMC5943504</ArticleId><ArticleId IdType="pubmed">29774215</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L.T., Bowser R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2017;14:119&#x2013;134. doi: 10.1007/s13311-016-0503-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0503-x</ArticleId><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Petzold A., Sussmuth S.D., Ludolph A.C., Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852&#x2013;856. doi: 10.1212/01.wnl.0000203120.85850.54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000203120.85850.54</ArticleId><ArticleId IdType="pubmed">16567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J., An J., Bowser R., Andersen P.M., Shaw C.E. pNfH is a promising biomarker for ALS. Amyotroph. Lateral Scler. Front. Degener. 2013;14:146&#x2013;149. doi: 10.3109/21678421.2012.729596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.729596</ArticleId><ArticleId IdType="pubmed">23134506</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K.B., Glass J.D., Crook J.E., Yang C., Thomas C.S., Desaro P., Johnston A., Overstreet K., Kelly C., Polak M., et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:467&#x2013;472. doi: 10.1136/jnnp-2012-303768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Henderson R.D., David M., McCombe P.A. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS ONE. 2016;11:e0164625. doi: 10.1371/journal.pone.0164625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodovitch A., Boucraut J., Delmont E., Parlanti A., Grapperon A.-M., Attarian S., Verschueren A. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS. Sci. Rep. 2021;11:703. doi: 10.1038/s41598-020-80370-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-80370-6</ArticleId><ArticleId IdType="pmc">PMC7803734</ArticleId><ArticleId IdType="pubmed">33436881</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M., Zhang L., Wang L., Granit V., Statland J., Barohn R., Swenson A., Ravits J., Jackson C., Burns T.M., et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69. doi: 10.1212/WNL.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Cao C., Qin X.-Y., Yu Y., Yuan J., Zhao Y., Cheng Y. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017;7:9094. doi: 10.1038/s41598-017-09097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09097-1</ArticleId><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., M&#xfc;ller K., Zondler L., Weydt P., Volk A.E., Bo&#x17e;i&#x10d; A.L., Walter M., Bonin M., Mayer B., von Arnim C.A.F., et al. Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain. 2014;137:2938&#x2013;2950. doi: 10.1093/brain/awu249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu249</ArticleId><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., M&#xfc;ller K., Zondler L., Weydt P., Mayer B., von Arnim C.A.F., H&#xfc;bers A., Dorst J., Otto M., Holzmann K., et al. Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiol. Aging. 2015;36:2660.e15&#x2013;2660.e20. doi: 10.1016/j.neurobiolaging.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.06.003</ArticleId><ArticleId IdType="pubmed">26142125</ArticleId></ArticleIdList></Reference><Reference><Citation>Waller R., Goodall E.F., Milo M., Cooper-Knock J., Da Costa M., Hobson E., Kazoka M., Wollff H., Heath P.R., Shaw P.J., et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS) Neurobiol. Aging. 2017;55:123&#x2013;131. doi: 10.1016/j.neurobiolaging.2017.03.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.03.027</ArticleId><ArticleId IdType="pmc">PMC5455071</ArticleId><ArticleId IdType="pubmed">28454844</ArticleId></ArticleIdList></Reference><Reference><Citation>Axisa P.-P., Hafler D.A. Multiple sclerosis. Curr. Opin. Neurol. 2016;29:345&#x2013;353. doi: 10.1097/WCO.0000000000000319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000319</ArticleId><ArticleId IdType="pmc">PMC7882195</ArticleId><ArticleId IdType="pubmed">27058221</ArticleId></ArticleIdList></Reference><Reference><Citation>Harbo H.F., Gold R., Tintor&#xe9; M. Sex and gender issues in multiple sclerosis. Ther. Adv. Neurol. Disord. 2013;6:237&#x2013;248. doi: 10.1177/1756285613488434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285613488434</ArticleId><ArticleId IdType="pmc">PMC3707353</ArticleId><ArticleId IdType="pubmed">23858327</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglione A., Zuccal&#xe0; M., Tosi M., Clerico M., Rolla S. Host Genetics and Gut Microbiome: Perspectives for Multiple Sclerosis. Genes. 2021;12:1181. doi: 10.3390/genes12081181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12081181</ArticleId><ArticleId IdType="pmc">PMC8394267</ArticleId><ArticleId IdType="pubmed">34440354</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg N., Smith T.W. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav. 2015;5:362. doi: 10.1002/brb3.362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.362</ArticleId><ArticleId IdType="pmc">PMC4589809</ArticleId><ArticleId IdType="pubmed">26445701</ArticleId></ArticleIdList></Reference><Reference><Citation>Ascherio A. Environmental factors in multiple sclerosis. Expert Rev. Neurother. 2013;13:3&#x2013;9. doi: 10.1586/14737175.2013.865866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.2013.865866</ArticleId><ArticleId IdType="pubmed">24289836</ArticleId></ArticleIdList></Reference><Reference><Citation>Types of MS|National Multiple Sclerosis Society.  [(accessed on 21 March 2022)].  Available online:  https://www.nationalmssociety.org/What-is-MS/Types-of-MS.</Citation></Reference><Reference><Citation>Milo R., Kahana E. Multiple sclerosis: Geoepidemiology, genetics and the environment. Autoimmun. Rev. 2010;9:A387&#x2013;A394. doi: 10.1016/j.autrev.2009.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.11.010</ArticleId><ArticleId IdType="pubmed">19932200</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelfand J.M. Multiple sclerosis. Handb. Clin. Neurol. 2014;122:269&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">24507522</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerlind H., Ramanujam R., Uvehag D., Kuja-Halkola R., Boman M., Bottai M., Lichtenstein P., Hillert J. Modest familial risks for multiple sclerosis: A registry-based study of the population of Sweden. Brain. 2014;137:770&#x2013;778. doi: 10.1093/brain/awt356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt356</ArticleId><ArticleId IdType="pmc">PMC3927700</ArticleId><ArticleId IdType="pubmed">24441172</ArticleId></ArticleIdList></Reference><Reference><Citation>Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 2005;37:1108&#x2013;1112. doi: 10.1038/ng1647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1647</ArticleId><ArticleId IdType="pubmed">16186814</ArticleId></ArticleIdList></Reference><Reference><Citation>Caillier S.J., Briggs F., Cree B.A.C., Baranzini S.E., Fernandez-Vi&#xf1;a M., Ramsay P.P., Khan O., Royal W., Hauser S.L., Barcellos L.F., et al. Uncoupling the Roles of HLA-DRB1 and HLA-DRB5 Genes in Multiple Sclerosis. J. Immunol. 2008;181:5473&#x2013;5480. doi: 10.4049/jimmunol.181.8.5473.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.181.8.5473</ArticleId><ArticleId IdType="pmc">PMC4346327</ArticleId><ArticleId IdType="pubmed">18832704</ArticleId></ArticleIdList></Reference><Reference><Citation>Greer J.M. The role of HLA in MS susceptibility and phenotype. Curr. Top. Behav. Neurosci. 2015;26:1&#x2013;27. doi: 10.1007/7854_2014_357/FIGURES/5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/7854_2014_357/FIGURES/5</ArticleId><ArticleId IdType="pubmed">25502788</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xe4;ger J., Schulze C., R&#xf6;sner S., Martin R. IL7RA haplotype-associated alterations in cellular immune function and gene expression patterns in multiple sclerosis. Genes Immun. 2013;14:453&#x2013;461. doi: 10.1038/gene.2013.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/gene.2013.40</ArticleId><ArticleId IdType="pubmed">23985573</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H., Huang J., Dou M., Liu Y., Xiao B., Liu X., Huang Z. Variants in the IL7RA gene confer susceptibility to multiple sclerosis in Caucasians: Evidence based on 9734 cases and 10436 controls. Sci. Rep. 2017;7:1207. doi: 10.1038/s41598-017-01345-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-01345-8</ArticleId><ArticleId IdType="pmc">PMC5430888</ArticleId><ArticleId IdType="pubmed">28446795</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryce G., Baker D. Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter? Mult. Scler. Relat. Disord. 2018;25:131&#x2013;137. doi: 10.1016/j.msard.2018.07.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2018.07.030</ArticleId><ArticleId IdType="pubmed">30071507</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemssen T., Ziemssen F. The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE) Autoimmun. Rev. 2005;4:460&#x2013;467. doi: 10.1016/j.autrev.2005.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2005.03.005</ArticleId><ArticleId IdType="pubmed">16137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziemssen T., Akg&#xfc;n K., Br&#xfc;ck W. Molecular biomarkers in multiple sclerosis. J. Neuroinflamm. 2019;16 doi: 10.1186/s12974-019-1674-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1674-2</ArticleId><ArticleId IdType="pmc">PMC6929340</ArticleId><ArticleId IdType="pubmed">31870389</ArticleId></ArticleIdList></Reference><Reference><Citation>Leurs C.E., Twaalfhoven H.A.M., Lissenberg-Witte B.I., van Pesch V., Dujmovic I., Drulovic J., Castellazzi M., Bellini T., Pugliatti M., Kuhle J., et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult. Scler. 2020;26:912. doi: 10.1177/1352458519845844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458519845844</ArticleId><ArticleId IdType="pmc">PMC7350201</ArticleId><ArticleId IdType="pubmed">31066634</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan B., Golderman S., Yahalom G., Yeskaraev R., Ziv T., Aizenbud B.M., Sela B.A., Livneh A. Free light chain monomer-dimer patterns in the diagnosis of multiple sclerosis. J. Immunol. Methods. 2013;390:74&#x2013;80. doi: 10.1016/j.jim.2013.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2013.01.010</ArticleId><ArticleId IdType="pubmed">23376556</ArticleId></ArticleIdList></Reference><Reference><Citation>Presslauer S., Milosavljevic D., Huebl W., Aboulenein-Djamshidian F., Krugluger W., Deisenhammer F., Senel M., Tumani H., Hegen H. Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: A multicenter study. Mult. Scler. J. 2016;22:502&#x2013;510. doi: 10.1177/1352458515594044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458515594044</ArticleId><ArticleId IdType="pubmed">26199348</ArticleId></ArticleIdList></Reference><Reference><Citation>Disanto G., Barro C., Benkert P., Naegelin Y., Sch&#xe4;delin S., Giardiello A., Zecca C., Blennow K., Zetterberg H., Leppert D., et al. Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 2017;81:857&#x2013;870. doi: 10.1002/ana.24954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24954</ArticleId><ArticleId IdType="pmc">PMC5519945</ArticleId><ArticleId IdType="pubmed">28512753</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunnarsson M., Malmestr&#xf6;m C., Axelsson M., Sundstr&#xf6;m P., Dahle C., Vrethem M., Olsson T., Piehl F., Norgren N., Rosengren L., et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann. Neurol. 2011;69:83&#x2013;89. doi: 10.1002/ana.22247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22247</ArticleId><ArticleId IdType="pubmed">21280078</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Khademi M., Fugger L., Lindhe &#xd6;., Novakova L., Axelsson M., Malmestr&#xf6;m C., Constantinescu C., Lycke J., Piehl F., et al. Inflammation-related plasma and CSF biomarkers for multiple sclerosis. Proc. Natl. Acad. Sci. USA. 2020;117:12952&#x2013;12960. doi: 10.1073/pnas.1912839117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1912839117</ArticleId><ArticleId IdType="pmc">PMC7293699</ArticleId><ArticleId IdType="pubmed">32457139</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N.A., Illes Z. Differentially expressed microRNA in multiple sclerosis: A window into pathogenesis? Clin. Exp. Neuroimmunol. 2014;5:149&#x2013;161. doi: 10.1111/cen3.12131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cen3.12131</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D., Wang W.-Z., Zhang X.-M., Yue H., Li B., Lin L., Fu J. MicroRNA Expression Aberration in Chinese Patients with Relapsing Remitting Multiple Sclerosis. J. Mol. Neurosci. 2014;52:131&#x2013;137. doi: 10.1007/s12031-013-0138-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-013-0138-x</ArticleId><ArticleId IdType="pubmed">24217794</ArticleId></ArticleIdList></Reference><Reference><Citation>Zailaie S.A., Siddiqui J.J., Al Saadi R.M., Anbari D.M., Alomari A.S., Cupler E.J. Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: A Systematic Review and Meta-Analysis. Immunol. Investig. 2021:1&#x2013;16. doi: 10.1080/08820139.2021.1887888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2021.1887888</ArticleId><ArticleId IdType="pubmed">33660581</ArticleId></ArticleIdList></Reference><Reference><Citation>Perdaens O., Dang H.A., D&#x2019;Auria L., van Pesch V. CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders. Neurol.&#x2014;Neuroimmunol. Neuroinflamm. 2020;7:e673. doi: 10.1212/NXI.0000000000000673.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000673</ArticleId><ArticleId IdType="pmc">PMC7051201</ArticleId><ArticleId IdType="pubmed">32033981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna J., Hossain G.S., Kocerha J. The Potential for microRNA Therapeutics and Clinical Research. Front. Genet. 2019;10 doi: 10.3389/fgene.2019.00478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2019.00478</ArticleId><ArticleId IdType="pmc">PMC6532434</ArticleId><ArticleId IdType="pubmed">31156715</ArticleId></ArticleIdList></Reference><Reference><Citation>Walgrave H., Zhou L., De Strooper B., Salta E. The promise of microRNA-based therapies in Alzheimer&#x2019;s disease: Challenges and perspectives. Mol. Neurodegener. 2021;16:76. doi: 10.1186/s13024-021-00496-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-021-00496-7</ArticleId><ArticleId IdType="pmc">PMC8572071</ArticleId><ArticleId IdType="pubmed">34742333</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769&#x2013;773. doi: 10.1038/nature03315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03315</ArticleId><ArticleId IdType="pubmed">15685193</ArticleId></ArticleIdList></Reference><Reference><Citation>Baek D., Vill&#xe9;n J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature. 2008;455:64&#x2013;71. doi: 10.1038/nature07242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07242</ArticleId><ArticleId IdType="pmc">PMC2745094</ArticleId><ArticleId IdType="pubmed">18668037</ArticleId></ArticleIdList></Reference><Reference><Citation>Selbach M., Schwanh&#xe4;usser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58&#x2013;63. doi: 10.1038/nature07228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07228</ArticleId><ArticleId IdType="pubmed">18668040</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W., Tan C., He Y., Zhang G., Xu Y., Tang J. Functional miRNAs in breast cancer drug resistance. OncoTargets Ther. 2018;11:1529&#x2013;1541. doi: 10.2147/OTT.S152462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/OTT.S152462</ArticleId><ArticleId IdType="pmc">PMC5865556</ArticleId><ArticleId IdType="pubmed">29593419</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercatelli N., Coppola V., Bonci D., Miele F., Costantini A., Guadagnoli M., Bonanno E., Muto G., Frajese G.V., De Maria R., et al. The Inhibition of the Highly Expressed Mir-221 and Mir-222 Impairs the Growth of Prostate Carcinoma Xenografts in Mice. PLoS ONE. 2008;3:e4029. doi: 10.1371/journal.pone.0004029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004029</ArticleId><ArticleId IdType="pmc">PMC2603596</ArticleId><ArticleId IdType="pubmed">19107213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gao D.-Y., Huang L. In vivo delivery of miRNAs for cancer therapy: Challenges and strategies. Adv. Drug Deliv. Rev. 2015;81:128&#x2013;141. doi: 10.1016/j.addr.2014.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2014.05.009</ArticleId><ArticleId IdType="pmc">PMC5009470</ArticleId><ArticleId IdType="pubmed">24859533</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R.U., Prieto-Vila M., Kohama I., Ochiya T. Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci. 2019;110:1140. doi: 10.1111/cas.13965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13965</ArticleId><ArticleId IdType="pmc">PMC6447849</ArticleId><ArticleId IdType="pubmed">30729639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty C., Sharma A.R., Sharma G., Lee S.-S. Therapeutic advances of miRNAs: A preclinical and clinical update. J. Adv. Res. 2021;28:127&#x2013;138. doi: 10.1016/j.jare.2020.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jare.2020.08.012</ArticleId><ArticleId IdType="pmc">PMC7753224</ArticleId><ArticleId IdType="pubmed">33364050</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Burt D., Gao G. Adeno-Associated Virus-Mediated MicroRNA Delivery and Therapeutics. Semin. Liver Dis. 2015;35:81&#x2013;88. doi: 10.1055/s-0034-1397352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1397352</ArticleId><ArticleId IdType="pmc">PMC4460833</ArticleId><ArticleId IdType="pubmed">25632938</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Deng J., Chu X., Zhao Y., Guo Y. Role of Post-Transcriptional Control of Calpain by miR-124-3p in the Development of Alzheimer&#x2019;s Disease. J. Alzheimer&#x2019;s Dis. 2019;67:571&#x2013;581. doi: 10.3233/JAD-181053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-181053</ArticleId><ArticleId IdType="pubmed">30584150</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Q., Zhang J., He F.-P., Bao W.-X., Zheng T.-T., Zhou D.-M., Pan H.-Y., Zhang H., Zhang X.-Q., He X., et al. Down-regulated expression of microRNA-338-5p contributes to neuropathology in Alzheimer&#x2019;s disease. FASEB J. 2019;33:4404&#x2013;4417. doi: 10.1096/fj.201801846R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201801846R</ArticleId><ArticleId IdType="pmc">PMC6404576</ArticleId><ArticleId IdType="pubmed">30576233</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai H., Fan W., Wang Y., Cai Y., Li X., Chen F., Chen X., Yang J., Tang P., Chen H., et al. Intranasal Administration of miR-146a Agomir Rescued the Pathological Process and Cognitive Impairment in an AD Mouse Model. Mol. Ther.&#x2014;Nucleic Acids. 2019;18:681&#x2013;695. doi: 10.1016/j.omtn.2019.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2019.10.002</ArticleId><ArticleId IdType="pmc">PMC6849368</ArticleId><ArticleId IdType="pubmed">31707205</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X. Current Strategies for Brain Drug Delivery. Theranostics. 2018;8:1481&#x2013;1493. doi: 10.7150/thno.21254.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.21254</ArticleId><ArticleId IdType="pmc">PMC5858162</ArticleId><ArticleId IdType="pubmed">29556336</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg T., Bhandari S., Rath G., Goyal A.K. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J. Drug Target. 2015;23:865&#x2013;887. doi: 10.3109/1061186X.2015.1029930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1061186X.2015.1029930</ArticleId><ArticleId IdType="pubmed">25835469</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F., Gernoux G., Sun H., Stock R., Blackwood M., Brown R.H., Mueller C. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci. Transl. Med. 2018;10 doi: 10.1126/scitranslmed.aau6414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aau6414</ArticleId><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu M., Lin Q., Huang L., Fu Y., Wang L., He S., Fu Y., Yang S., Zhang Z., Zhang L., et al. Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson&#x2019;s disease. J. Control. Release. 2018;287:156&#x2013;166. doi: 10.1016/j.jconrel.2018.08.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jconrel.2018.08.035</ArticleId><ArticleId IdType="pubmed">30165139</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H., Sun T., An J., Wen L., Liu F., Bu Z., Cui Y., Feng J. Potential Roles of Exosomes in Parkinson&#x2019;s Disease: From Pathogenesis, Diagnosis, and Treatment to Prognosis. Front. Cell Dev. Biol. 2020;8 doi: 10.3389/fcell.2020.00086.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00086</ArticleId><ArticleId IdType="pmc">PMC7047039</ArticleId><ArticleId IdType="pubmed">32154247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>